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Abstract: Obesity is a chronic disease with a high prevalence in both developed and developing 
countries. Effective management of this worldwide epidemic will have a significant impact on 
the health care system globally. Lifestyle interventions, such as restricting calorie consumption 
and increasing physical activity, remain a major component of weight-reduction programs. The 
development of pharmacotherapy for the management of obesity is still at the infancy stage. 
Side effects have been the key issue for anti-obesity drugs previously withdrawn from the 
market. The focus of this review, lorcaserin, is a selective serotonin receptor agonist that is 
currently undergoing Phase III evaluations. The efficacy of this drug in reducing body weight 
and improving metabolic parameters of obese patients has been demonstrated in two recent 
clinical trials. The available evidence indicates that this drug does not show unwanted effects 
on heart valves or pulmonary artery pressure, and the treatment improves the risk factors for 
type 2 diabetes and cardiovascular diseases. Despite these promising results, additional experi-
mental and clinical studies are critical for the approval of lorcaserin as a new anti-obesity 
monodrug therapy by the US Food and Drug Administration.
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Introduction: pharmacotherapy  
for obesity management
Obesity, a chronic pathological condition of abnormal or excessive fat accumulation 
in the body, has become a worldwide pandemic. The most commonly adopted method 
to measure obesity is by calculating body mass index (BMI), defined as a person’s 
weight in kilograms divided by the square of their height in meters. Individuals with 
a BMI equal to or more than 30 are classified as obese, whereas those with a BMI 
between 25 and 29.9 are classified as overweight.1 Obesity has received considerable 
attention as a major public health hazard. It is most prevalent in Western societies, 
but a rapid increase is also seen in the developing world.2 The latest World Health 
Organization projections have indicated that whereas in 2005 at least 1 in 3 of the 
world’s adult population was overweight and almost 1 in 10 was obese, by 2015 
approximately 2.3 billion adults will be overweight and more than 700 million will 
be obese. Importantly, the alarming increase in the prevalence of obesity has also been 
observed in children. The worldwide prevalence of childhood overweight and obesity 
increased from 4.2% in 1990 to 6.7% in 2010. This trend is expected to reach 9.1%, 
or approximately 60 million, in 2020.3
Overweight and obesity are major risk factors for a wide range of serious health 
consequences, including cardiovascular diseases (heart failure and stroke), diabetes, 
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dyslipidemia, obstructive sleep apnea, asthma,  musculoskeletal 
disorders, and cancers.4 Obesity has become a leading cause 
of preventable death, second only to tobacco.5 Current strate-
gies for controlling body weight include diet, exercise, drug 
therapy, bariatric surgery, or combinations of the above.6 
The fundamental principle for weight management is to 
reduce energy intake and/or increase expenditure. Lifestyle 
changes and regular exercise facilitate weight loss and 
improve metabolic, cardiac, and vascular functions in obese 
patients.7 For example, modest weight loss of as little as 5% 
results in a significant reduction in incidence of type 2 
 diabetes.8 The blood pressure reduction achieved by adequate 
weight loss is equivalent to that obtained by using low-dose 
pharmacological therapy.9 Weight loss has also been shown to 
improve liver function in patients with nonalcoholic fatty liver 
disease.10,11 Unfortunately, failure to maintain changes in diet 
and exercise patterns is a major reason for weight regain 
experienced in most people. Bariatric surgery, generally used 
for patients with morbid obesity (BMI equal to or more 
than 40), is effective for sustaining weight loss but often 
causes complications.12,13 Pharmacotherapy, combined with 
lifestyle intervention, has demonstrated efficacy in weight 
loss.14 The general guidelines recommend drug therapy for 
obesity when the BMI is equal to or more than 30 or when 
the BMI is between 27.0 and 29.9 with a major obesity- related 
comorbidity (eg, hypertension, diabetes, and obstructive 
sleep apnea). Despite these strategies, obesity and its associ-
ated health complications remain widely  prevalent, and 
effective treatment is desperately needed to target specific 
physiologic pathways.
There are several anti-obesity drugs on the market for 
 short-term usage. Currently, only one drug is approved by the 
US Food and Drug Administration (FDA) for long-term main-
tenance of weight loss (Table 1).15 Orlistat (Xenical [Roche 
Laboratories, Nutley, NJ, USA] and over-the-counter Alli 
[GlaxoSmithKline, Philadelphia, PA, USA]) blocks caloric 
absorption of the ingested fat by inhibiting gastric and pancre-
atic lipases in the gut lumen.16 The inactivated enzymes cannot 
hydrolyze dietary fat in the form of triglycerides into absorbable 
free fatty acids and monoglycerides, which may have a positive 
effect on weight control. Orlistat is prescribed for obese patients 
with a BMI of 30 or more. Additionally, patients with a BMI 
of 27 or higher and who have other risk factors, including 
hypertension, diabetes, and dyslipidemia, are indicated to take 
this drug combined with a reduced-calorie diet. The systemic 
adverse effects of orlistat are rare. It is available at half the 
dose as an over-the-counter preparation. Orlistat can reduce 
the absorption of fat-soluble vitamins and beta-carotene. Thus, 
vitamin supplementation is recommended.16 An efficacy in 
inducing weight loss of up to 8%–10% has been demonstrated 
for orlistat.17 However, patients often regain weight upon dis-
continuation of the medication, and there are no long-term safety 
or efficacy data available for using this drug beyond 2 years.
 This review focuses on a centrally acting drug, lorcaserin, 
which is an anorectic weight-loss agent acting as a selective 
serotonin receptor 2C agonist and currently undergoing Phase III 
clinical trials.18 In particular, its pharmacology (including action 
mechanisms, pharmacokinetics, efficacy, and drug safety) and 
patient-focused perspectives (such as quality of life, satisfac-
tion, acceptability, adherence, and uptake) will be discussed.
Table 1 Drugs approved by the US Food and Drug Administration for obesity treatment
Generic name Mechanism of action Usage Common side effects
Orlistat Lipase inhibitor Long-term treatment  
(up to 12 months) for 
adults and children  
age 12 years and older
Gastrointestinal symptoms (cramping, diarrhea, oily 
spotting), reduced absorption of fat-soluble vitamins 
Diethylpropion Appetite suppressant Short-term treatment  
(up to 12 weeks) for adults
Precordial pain, elevation of blood pressure,  
blurred vision, dizziness, anxiety, depression, 
abdominal discomfort 
Phentermine Appetite suppressant Short-term treatment  
(up to 12 weeks) for adults
Primary pulmonary hypertension and/or regurgitant 
cardiac valvular disease, dry mouth, unpleasant taste, 
diarrhea, constipation, vomiting, headache, insomnia, 
shortness of breath, chest pain, overstimulation 
Benzphetamine Appetite suppressant Short-term treatment  
(up to 12 weeks) for adults
Palpitation, tachycardia, elevation of blood pressure, 
overstimulation, dizziness, insomnia, tremor, 
sweating, headache, depression following withdrawal 
of the drug, dryness of the mouth, unpleasant taste, 
nausea, diarrhea
Phendimetrazine Appetite suppressant Short-term treatment  
(up to 12 weeks) for adults
insomnia, hyperactivity, and blurred vision, increased 
blood pressure and heart rates, overstimulation
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5-hydroxytryptamine (5HT) 
receptor and agonists
Managing the natural inclination to eat is important for weight- 
loss therapy. The hypothalamus appears to be a major center 
responsible for regulating hunger and food intake.19 
 Monoaminergic neurotransmitters, including dopamine, 
serotonin (5-hydroxytryptamine, 5-HT), and norepinephrine, 
mediate the signals for appropriate adjustments of food con-
sumption.20 Stimulation of specific central serotonin recep-
tors represents an effective pharmacological mechanism to 
suppress  appetite.21 The 5-hydroxytryptamine 2 (5HT
2
) 
receptor, a member of the G-protein-coupled receptor fam-
ily, is the target for a variety of centrally acting anti-obesity 
drugs.22–24 The 5HT
2
 receptor family members 5HT
2A
, 5HT
2B
, 
and 5HT
2C
 distribute in different tissues and elicit distinctive 
biological activities.25 5HT
2A
 is located in the central nervous 
system (CNS, mainly the cortex and hippocampus), cardiac 
vessels, and heart valves.26 Most 5HT
2B
s are found in the 
cardiovascular system.27 Stimulation of 5HT
2B
 may cause 
cardiomyopathy and endocardial fibrosis of cardiac valves.28 
The 5HT
2C
 receptor shows high homology and similar phar-
macological binding profiles to the 5HT
2A
 receptor.29 5HT
2C
 
is almost exclusively located in the CNS and participates in 
the process of controlling caloric balance. Suppression of 
appetite is predominantly mediated by the 5-HT
2C
 receptor, 
which is the target for anti-obesity treatment.30
Drugs targeting the 5-HT system have a long history in 
the management of obesity. The nonspecific 5HT
2
 agonists 
fenfluramine and dexfenfluramine were approved by the FDA 
for the treatment of obesity in 1973 and 1996, respectively. 
These weight-loss drugs became extremely popular for 
weight control and were commonly used in combination with 
phentermine. However, by 1997 both drugs were removed 
from the US market due to valvular heart diseases and pul-
monary hypertension. These adverse effects are thought to 
occur through agonism of the 5-HT
2B
 receptor expressed on 
cardiac valvular interstitial cells and pulmonary artery 
smooth muscle cells.31 Given the specific activity of 5-HT
2C
 
in appetite suppression, more selective agents that work on 
this receptor but with few or no effects on the 5HT
2B
 or 5HT
2 A
 
are being developed for obesity therapy.
Lorcaserin: mode of action  
and pharmacokinetics
Lorcaserin ((1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl- 
1H-3 benzazepine), developed by Arena Pharmaceuticals 
(San Diego, CA, USA), is a novel and selective 5-HT
2C
 full 
agonist with ∼15- and ∼100-fold higher affinity (K
i
 = 15 ± 1nM) 
over those of 5-HT
2A
 and 5-HT
2B
 receptors.18,32 Lorcaserin 
differs from the earlier nonselective serotonin agonists fen-
fluramine and dexfenfluramine, in that it exerts minimal 
activity on 5-HT
2A
 and 5-HT
2B
 receptors, which mediate the 
pathogenesis of serotonergic valvulopathy.18 Lorcaserin is 
indicated to promote weight loss in an obese population. 
Combined lorcaserin with a reduced-calorie diet and regular 
exercise is suggested for treating obese patients with a BMI 
of 30 or more and overweight patients with a BMI of 27 or 
higher and in the presence of at least one weight-related risk 
factor such as hypertension, dyslipidemia, cardiovascular 
disease, glucose intolerance, and sleep apnea.33 The recom-
mended clinical dose of lorcaserin is 10 mg twice daily, and 
the intended patient population is adults aged 18 years and 
older. Following oral administration (twice daily [b.i.d.]), 
more than 90% of lorcaserin can be rapidly absorbed. Time 
to reach maximum plasma concentration is approximately 
1.5 to 2 hours, and its half-life (T
1/2
) is about 11 hours. 
Approximately 70% of drugs are bound to plasma protein. 
The volume of distribution in the body is ∼252 L in a 92.5 kg 
subject.34 In both animals and human subjects, the brain is 
exposed to a much higher concentration of lorcaserin than 
that in plasma. The steady ratio of brain to plasma is 10 and 
24 in the monkey and rat, respectively.18,35 Lorcaserin is mainly 
metabolized in the liver and excreted by the kidney. The major 
circulating metabolite is the sulfamate of lorcaserin (M1), 
and the major urinary metabolite is N-carbamoyl glucuronide 
(M5).34 Gender, race, age, and BMI have no significant effects 
on lorcaserin pharmacokinetics. In patients with renal impair-
ment, lorcaserin and its metabolites increases by approxi-
mately 1.7- to 6-fold and cannot be removed from the 
circulation by hemodialysis. Hepatic dysfunction prolongs 
the plasma T
1/2
 of lorcaserin by about 5–9 hours. Lorcaserin 
is a mild to moderate inhibitor of CYP2D6; thus, the interac-
tion potential with drugs such as dextromethorphan and 
desipramine should be noted during drug combinations.36,37
Lorcaserin: clinical trials
The clinical data comparing lorcaserin with other medications 
or in combination with other medications for the treatment 
of obesity are currently not available. Information can 
be obtained from one Phase II APD356-004 study and one 
Phase III clinical trial program (Behavioral Modification and 
Lorcaserin for Overweight and Obesity Management 
[BLOOM]) that evaluated more than 3000 patients treated 
with this drug for up to 2 years.33,38
APD356-004 trial (NCT00116740) was a randomized, 
doubled-blinded, placebo-controlled, parallel-arm study to 
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evaluate the efficiency and safety of lorcaserin.38 This trial 
enrolled 469 obese patients aged between 18 and 65 years 
and with a BMI of 30–45. Patients with diabetes or other 
chronic diseases were excluded. Patients maintained their 
usual diet and exercise habits throughout the study. They 
were given placebo or lorcaserin at 10 mg every day (q.d.), 
15 mg q.d., or 10 mg b.i.d. for 12 weeks. The efficiency was 
evaluated by the weight changes of the endpoint compared 
with the baseline. The proportions of patients achieving more 
than 5% reduction from their initial body weight were 12.8%, 
19.5%, and 31.2% in the 10 mg q.d., 15 mg q.d., and 10 mg 
b.i.d. groups treated with lorcaserin, with average weight 
losses of 1.8 kg, 2.6 kg, and 3.6 kg, respectively. However, 
only 2.3% patients in the placebo group lost more than 5% 
body weight, and the mean weight loss was 0.3 kg. In 
 addition, BMI, total cholesterol, and waist circumference 
were decreased significantly in patients with lorcaserin 
15 mg q.d. and 10 mg b.i.d. No significant valvular changes 
were detected by echocardiogram in patients treated with 
lorcaserin. The most common adverse effects were headache, 
nausea, and dizziness.38 Lorcaserin was identified as an effec-
tive drug for weight reduction in this 12-week study.
Long-term efficacy was assessed in one Phase III trial, 
BLOOM, which met the FDA Guidance for Industry Devel-
oping Products for Weight Management in February 2007.33 
It was designed as a 104-week, double-blind, placebo- 
controlled clinical trial to assess the safety and efficacy of 
lorcaserin. A total of 3182 male and female patients between 
the ages of 18 and 65 years with a BMI of 30–45 with or 
without a comorbid condition, or a BMI of 27–29.9 with at 
least one comorbid condition, were included. Patients with 
pre-existing valvulopathy identified by echocardiograms 
were excluded. Diabetes mellitus was also one of the key 
exclusion criteria. They were randomly assigned to receive 
lorcaserin (10 mg) or placebo b.i.d., in combination with a 
diet and exercise program. After 1 year, the proportion of 
patients achieving more than 5% weight loss was 47.5% and 
20.3% in lorcaserin and placebo groups, respectively. The 
mean weight reduction was 5.8 ± 0.2 kg in patients treated 
with lorcaserin 10 mg b.i.d. and 2.2 ± 0.1 kg in patients treated 
with placebo. At week 52, 22.6% of patients in the lorcaserin 
group achieved more than 10% weight loss from baseline, 
compared with 7.7% of patients treated with placebo.
At the end of year 1, patients receiving lorcaserin were 
randomized in a 2:1 ratio to either remain in the lorcaserin 
treatment group or to switch to placebo for the second year. 
Patients receiving placebo in year 1 remained on placebo in 
year 2. The year 2 study was to assess the ability of lorcaserin 
to maintain body weight loss achieved during year 1. Among 
those who had weight loss of 5% or more, the weight loss 
was maintained in a greater proportion of patients who con-
tinued to receive lorcaserin in year 2 than in those who were 
reassigned to receive placebo (67.9% versus 50.3%). The 
mean body weight among patients who received lorcaserin 
both years was lowest compared with patients who received 
placebo in both years or patients receiving lorcaserin in year 1 
and placebo in year 2. By contrast, the patients switched from 
lorcaserin to placebo gained back the lost weight. Approxi-
mately the same body weight was found at year 2 as those 
who had received placebo for both years. Lorcaserin therapy 
resulted in clinically relevant improvements in almost all 
reported surrogate measures of type 2 diabetes and cardio-
vascular risk. It reduced the waist  circumference as well as 
total cholesterol, low-density lipoprotein (LDL) cholesterol, 
and triglyceride. Moreover, high-sensitivity C-reactive 
 protein, a marker of cardiovascular risk, was significantly 
decreased by about 1.2 mg/L compared with baseline in the 
lorcaserin group in year 1, but not in the placebo group. The 
waist circumference and BMI, and the fasting glucose, insulin, 
total cholesterol, LDL cholesterol, and triglyceride levels, 
were decreased significantly in the lorcaserin-treated group.
Arena Pharmaceuticals conducted another Phase III trial, 
BLOOM-DM (Behavioral Modification and Lorcaserin for 
Overweight and Obesity Management in Diabetes Mellitus). 
The BLOOM-DM study evaluated 604 obese and overweight 
patients with type 2 diabetes. Patients were randomized to 
receive lorcaserin 10 mg b.i.d., lorcaserin 10 mg q.d., or 
placebo for 1 year. The briefing document for the FDA Advi-
sory Committee Meeting (NDA 22-529) included the fol-
lowing information, which had not been peer reviewed. At 
week 52, 37.5% of patients treated with lorcaserin 10 mg 
b.i.d achieved at least a 5% weight reduction, more than 
double the 16.1% of patients taking placebo. Mean weight 
loss was 4.7 kg in the lorcaserin group and 1.6 kg in the 
placebo group. A total of 16.3% of patients taking lorcaserin 
10 mg b.i.d achieved at least 10% weight loss compared with 
4.4% of patients treated with placebo. Lorcaserin patients 
achieved statistically significant improvements relative to 
placebo in fasting glucose and glycated hemoglobin. Changes 
in fasting insulin, triglycerides, total cholesterol, high-density 
lipoprotein cholesterol, LDL cholesterol, and systolic and 
diastolic blood pressure were not significant.
Lorcaserin: efficacy versus safety
During the past several decades, most drugs for obesity treat-
ment initially achieved regulatory approval, but when they 
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reached the market they were subsequently withdrawn owing 
to serious adverse effects.39,40 For example, in 2007, the 
 cannabinoid receptor antagonist rimonabant was withdrawn 
from the market because of an increased risk of depression, 
 anxiety, and suicidal ideation.41 In January 2010, the 
 European Medicine Agency Committee for Medicinal Prod-
ucts for Human Use recommended that the use of sibutramine 
(Meridia, Abbott Laboratories, North Chicago, IL, USA) be 
suspended based on the preliminary report from the 10,000-
patient, 6-year Sibutramine Cardiovascular  Outcome Trial 
(SCOUT; ClinicalTrials.gov number, NCT00234832), which 
showed an increased risk of cardiovascular events with 
sibutramine as compared with placebo.42 In October 2010, 
the FDA completed a review of the potential benefits and 
risks of Meridia and requested Abbott Laboratories to with-
draw the drug from the market. Drugs targeting the seroton-
ergic system have also had a history of being withdrawn. 
Fenfluramine and dexfenfluramine were removed from the 
market following reports of serious adverse events, including 
valvular heart disease, and an increased risk of pulmonary 
arterial hypertension.43–45
Compared with the lipase inhibitor orlistat, the weight-
loss efficacy of lorcaserin was slightly less.39 However, the 
safety and adverse event profiles of lorcaserin seem to be 
better.46,47 Treatment with this drug results in more beneficial 
effects on risk factors for type 2 diabetes and cardiovascular 
disease, including blood pressure, heart rate, and levels of 
LDL cholesterol. In the BLOOM trial, patients taking lorca-
serin did not seem to have increased risk of valvulopathy, 
pulmonary hypertension, depression, or suicidal ideation.33 
In year 1 of the BLOOM trial, the incidence rate of valvul-
opathy was 2.3% and 2.7% in the placebo and lorcaserin 
groups, respectively. In year 2, the proportion of valvulopathy 
was 2.7% in patients treated with placebo and 2.6% in 
patients receiving lorcaserin in both years. Similar changes 
in mean pulmonary artery systolic pressure were observed 
in all study groups. However, it should be noted that the study 
was slightly underpowered regarding the primary safety 
endpoint of echocardiography.33 The most common adverse 
events in the lorcaserin group are upper respiratory infections, 
headache, dizziness, and nausea. The incidences of headache 
and dizziness were 18% and 8.2%, respectively, in the lor-
caserin group, compared with 11% and 3.8% in the placebo 
group in year 1. During year 2, the rates of headache were 
similar among all treatment groups.33 It was also reported 
that the headache and dizziness tended to be self-limited, 
mild, or moderate in severity.38 No apparent drug-related 
heart and artery dysfunction was observed during the 
APD356-004 study. The patients with increased or decreased 
regurgitation did not differ between the placebo and lorca-
serin groups. Additionally, in all groups, the frequencies of 
change in mean systolic pulmonary artery pressures more 
than 5 mmHg were similar.38 In the BLOOM-DM trial, the 
most frequent adverse events included headache (14.5% 
patients of the lorcaserin group versus 7.1% patients in the 
placebo group), upper respiratory infection (13.7% versus 
14.7%), back pain (11.7% versus 7.9%), and nasopharyngitis 
(11.3% versus 9.9%). Hypoglycemia, including both asymp-
tomatic low blood glucose measurements and symptomatic 
events, was 29.3% and 21.0% for lorcaserin 10 mg b.i.d. and 
placebo groups, respectively. Valvulopathy was seen in 2.5% 
of lorcaserin (10 mg b.i.d.) patients and 1.9% of placebo 
patients at week 24, and 2.9% of lorcaserin (10 mg b.i.d.) 
patients and 0.5% of placebo patients at week 52.
Five cases of serious adverse events were reported in the 
APD356-004 trial, including one kidney stone and pneumo-
nia in the same patient receiving placebo treatment, one report 
of depression in a patient with a prior mood disorder history 
in the lorcaserin group, and a new-onset seizure on study day 
71 in a patient taking lorcaserin 10 mg b.i.d.38 In the BLOOM 
trial there was a similar frequency in serious adverse events 
among the three study groups. During year 1, the incidence 
of depression, depressive symptoms, or depressed mood was 
2.5% in the lorcaserin group compared with 2.2% in the 
placebo group. In year 2, the rates of depressive symptoms 
were 3.0%, 2.0%, and 2.8% in patients given lorcaserin for 
2 years, patients receiving placebo in both years, and patients 
given placebo in year 2 after 1 year’s lorcaserin 
treatment.33
Lorcaserin was generally well accepted. In the APD356-
004 trial, around the same number of patients completed the 
12-week study. The proportion of discontinued patients was 
22% in placebo group and 21% in lorcaserin 10 mg q.d., 
slightly less than 27% with lorcaserin 15 mg q.d. and 10 mg 
b.i.d. The most frequent reasons for study withdrawal were 
patient choice or being lost to follow-up.38 In the BLOOM 
study, only about 50% and 36% of the randomly assigned 
patients completed the first and second year of the study, 
respectively. The rate of completion at year 1 was 55.4% in 
the lorcaserin group and 45.1% in the placebo group, although 
this was similar to the rate in other large, long-term, random-
ized trials of obesity.33,47 The proportion of patients who 
discontinued the study because of adverse events was 7.1% 
and 6.7% in the lorcaserin and placebo groups,  respectively. 
Headache and dizziness were major causes. The overall rate 
of completion of year 2 study was 72.6% of patients who 
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completed year 1 study. The rates and reasons for discontinu-
ation during year 2 were similar among the three groups.
In summary, more Phase III studies will be required to 
confirm these initial findings in larger populations of patients.
Limitation and future prospective
According to the FDA Guidance for Industry Developing 
Products for Weight Management, a product considered to be 
effective after 1 year of treatment should satisfy two efficiency 
endpoints.48 The primary efficacy endpoint refers to the dif-
ference in mean weight loss between the active product- and 
placebo-treated groups being at least 5% and statistically 
significant. Moreover, the proportion of subjects who lose 
5% of baseline body weight in the active product group is 
at least 35%, or approximately double the proportion in the 
placebo-treated group, and the difference between groups is 
statistically significant. The second criterion of efficacy end-
point is that changes in the metabolic parameters, such as but 
not limited to blood pressure, lipids profile, glucose and insulin 
levels, and waist circumference, should be factored into effi-
ciency assessment. In the BLOOM trial, although the weight 
loss observed in the lorcaserin-treated groups was associated 
with improvements of lipid profiles and a reduction in waist 
circumference and BMI, the percentage of patients who 
achieved equal to or more than a 5% reduction of body weight 
was not reaching the criteria to differentiate the active product 
and placebo groups.33
According to the announcement released by Arena Phar-
maceuticals on September 16, 2010, the FDA Advisory Com-
mittee discussed the safety and efficacy of the lorcaserin trial. 
The drug was rejected by a vote of nine to five due to the 
concern that weight loss efficacy in nondiabetic overweight 
and obese subjects was marginal. In addition, animal studies 
suggested that lorcaserin may cause tumors in rats. There was 
uncertainty in the classification of mammary masses, an 
unresolved exposure–response relationship for lorcaserin-
emergent mammary adenocarcinoma, and an unidentified 
mode of action and unclear safety margin for lorcaserin-
emergent brain astrocytoma. In clinical studies, evidence 
could not be provided to alleviate concerns regarding the 
relevance of the tumor findings in rats. Recently, Arena Phar-
maceuticals announced the findings from the 1-year BLOOM- 
DM trial, demonstrating statistically  significant weight loss 
in obese and overweight type 2 diabetic patients who met all 
three co-primary efficacy endpoints. However, a higher rate 
of valvulopathy was noted (2.9% of patients with lorcaserin 
[10 mg b.i.d.] compared with 0.5% of patients with placebo 
at week 52). These data need to be peer reviewed and analyzed 
together with the previous clinical findings. At this stage, 
whether the concerns can be addressed and lorcaserin will be 
approved as a treatment for obesity remains unpredictable. 
Clearly, more basic research and clinical studies are required, 
especially to clarify the mechanism of tumor development in 
animals and to assess the uncertain risk in humans. Informa-
tion regarding the distribution of lorcaserin in the CNS of 
both animals and human subjects would help to clarify the 
astrocytoma exposure margins. In addition, whether the 
weight loss effects of lorcaserin will be able to translate into 
clinical health benefits, especially the metabolic and cardio-
vascular outcomes, is a separate question.
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